Quotient Bioresearch will showcase its technologies and services for early drug development at the American Association of Pharmaceutical Scientists (AAPS) 2009 Annual Meeting and Exposition.
At the event, Quotient will highlight the 14C Synthesis-to-Clinic service and its Translational Pharmaceutics platform.
The 14C Synthesis-to-Clinic service simplifies the procurement of regulatory and non-regulatory 14C studies to support drug-development needs.
Translational Pharmaceutics is an integrated formulation development, drug-product manufacturing and clinical-testing platform.
It increases the efficiency and precision with which an optimised oral drug product can be identified for further development and results in reduced development timelines and associated cost savings.
Quotient can also offer: 14C Custom Synthesis - the manufacture of custom 14C radio-labelled drug compounds (final products and intermediates); pre-clinical metabolism - a full range of in vivo and in vitro metabolism studies covering all FDA guidelines; early clinical - first-in-human through to proof of concept; bioanalytical sciences - spanning small molecules, biopharmaceuticals, biomarkers, clinical laboratory support and microbiology.
Quotient will also run: nine poster presentations covering a range of early development case studies; an open forum session entitled 'An Evolution or Revolution in Drug Metabolism' on 12 November; and a social/networking evening on 9 November for more than 200 clients and collaborators.
